Table 1. PICOS inclusion criteria and exclusion criteria applied to database search.

PICOS	Inclusion criteria	Exclusion criteria
Population
Intervention	• SGLT2 inhibitors, including empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin, sotagliflozin, and licogliflozin
Comparison	• Comparison of SGLT2 inhibitors with a control group (placebo) on their effect on cardiovascular imaging parameters
Outcome	• LA parameters: LAM, LAMi, LAD, and LA size
	• LVM parameters: LVM and LVMi
	• LV volume parameters: LVESV, LVESVi, LVEDV, and LVEDVi
	• LV function parameters: LVEF, LVGLS, LVGLSi, and stroke volume
	• Others: extracellular volume fraction, LV internal diameter, aortic root diameter, mitral E velocity, mitral annulus velocity, E/A, E/e′, and pulmonary artery systolic pressure
Study design	• Articles in English or translated to English	• Mixed methods research, meta-analyses, systematic reviews, cohort studies, case-control studies, cross-sectional studies, and descriptive papers
	• Randomised controlled trials	• Case reports and series, ideas, editorials, and perspectives
	• Conference abstracts or electronic and print information not controlled by commercial publishing, reporting on randomized controlled trials
	• Year of Publication: Date of inception, February 28, 2021
	• Databases: PubMed, Embase, Cochrane, Scopus

LA: left atrial, LAD: left atrial diameter, LAM: left atrial mass, LAMi: left atrial mass index, LVEDV: left ventricular end-diastolic volume, LVEDVi: left ventricular end-diastolic volume index, LVEF: left ventricular ejection fraction, LVESV: left ventricular end-systolic volume, LVESVi: left ventricular end-systolic volume index, LVGLS: left ventricular global longitudinal strain, LVM: left ventricular mass, LVMi: left ventricular mass index, PICOS: Populations, Intervention, Comparison, Outcomes, and Study, SGLT2: sodium-glucose cotransporter 2.